Indications for photodynamic therapy? Since other anti-angiogenic drugs such as Lucentis are not yet available in China, photodynamic therapy is currently the only drug legally available in China. Its main indications are as follows: 1, choroidal neovascularization in and around the macula from various causes (age-related macular degeneration, mid-bleeding, high myopia, etc., fundus vascular-like streaks, choroidal neovascularization caused by choroidal osteoma, etc.). 2, certain intraocular tumors, such as choroidal hemangioma, choroidal melanoma, optic papillary hemangioma). 3, polypoidal choroidal vasculopathy (PCV): often a large amount of hemorrhage deep in the fundus, similar to age-related macular degeneration. 4, retinal hemangioma, retinal hemangioma-like proliferation. 5, central plasmacytoid chorioretinopathy (“mesoplasm”) 6, optic papillary neovascularization, abnormal retinal vessels in Coats’ disease (conventional laser does not work due to massive exudation) Precautions for photodynamic therapy? 1.Before treatment: you need to prepare sunglasses, gloves, wear long-sleeved clothing and pants, and bring a headband or hat 2.After treatment: avoid strong light exposure for 48 hours. 3.After the surgery, regular review should be done according to the physician’s order, which is crucial. Generally, each review requires OCT examination, and fundus angiography should be done once in 3 months. Other issues to be explained 1. The treatment of choroidal neovascularization under the central macular recess (including age-related macular degeneration, pathological myopia with choroidal neovascularization, “mid-bleed”, etc.) is a worldwide problem, especially age-related macular degeneration, which has been the primary cause of blindness in developed countries and is also an important cause of blindness in the elderly in China. There is no particularly effective treatment method, especially the general oral drug treatment is basically ineffective. The biggest advantage of photodynamic therapy over intraocular injections (such as Lucentis or Avastin) is that it has almost no side effects or complications. Hospitalization is generally not required. 3, photodynamic therapy used by the photosensitizer, Vizudar, is an imported drug, the biggest problem is that the price of the drug is relatively expensive, nearly 16,000 yuan, is not yet covered by health insurance. 4, photodynamic therapy, for the elimination of choroidal neovascularization is really effective, but really can not guarantee a substantial improvement in vision, mainly to keep the patient’s condition stable, not out of control and rapid deterioration, but also can not stop the recurrence of their lesions, therefore, many patients need to repeat photodynamic therapy. 5, photodynamic therapy, if combined with anti-angiogenic drugs intraocular injection, can reduce the number of photodynamic therapy treatment, reduce the cost and reduce the complications.